Aeon Biopharma, INC 8-K filings

AEON Biopharma is developing PrabotulinumtoxinA as a biosimilar to Botox, aiming for approval across all 12 therapeutic indications and a significant share of the $2.5 billion US market.

AEON Biopharma will pursue a biosimilar regulatory pathway for its lead candidate, ABP-450, using BOTOX as a reference product, focusing on a pivotal study in cervical dystonia.

AEON Biopharma held its annual meeting on June 14, 2024, where stockholders elected two Class I directors, approved a potential share issuance to Daewoong Pharmaceuticals, and ratified the appointment of KPMG as the independent auditor.

AEON Biopharma has terminated its CFO's consulting agreement, appointed a new principal financial officer and principal accounting officer, and discontinued its Phase 2 migraine study to conserve cash.

AEON Biopharma announced its first quarter 2024 financial results and provided a business update, noting that a Phase 2 study of ABP-450 for chronic migraine did not meet its primary or secondary endpoints.

AEON Biopharma has announced a restatement of its previously issued financial statements for the three and nine months ended September 30, 2023, and the year ended December 31, 2023, due to an accounting error related to in-process research and development.

AEON Biopharma's Phase 2 trial of ABP-450 for chronic migraine did not meet its primary endpoint, showing no statistically significant difference between the drug and placebo.

AEON Biopharma has closed a $10 million convertible note financing with Daewoong Pharmaceutical and appointed Seongsoo Park, CEO of Daewoong, to its Board of Directors.

AEON Biopharma has calculated the Redemption Fair Market Value for its public warrants at $7.6994, with a redemption date of April 29, 2024.

AEON Biopharma announced the redemption of all outstanding public warrants, requiring a cashless exercise by holders before the April 29, 2024 deadline.

AEON Biopharma reports a successful end-of-Phase 2 meeting with the FDA for its migraine treatment program and secures $15 million in private funding.

AEON Biopharma has secured a $5 million senior secured convertible note from Daewoong Pharmaceutical to support clinical development and working capital.

AEON Biopharma has entered into a $15 million senior secured convertible note financing agreement with Daewoong Pharmaceutical and received FDA alignment on its Phase 3 migraine program.

AEON Biopharma has announced a restatement of its previously issued financial statements for the three and nine months ended September 30, 2023, due to calculation errors, and also expressed substantial doubt about its ability to continue as a going concern.